Capturing the enthesitis related arthritis contemporary profile of Caucasian patients in the era of biologics.
Τίτλος | Capturing the enthesitis related arthritis contemporary profile of Caucasian patients in the era of biologics. |
Publication Type | Journal Article |
Year of Publication | 2020 |
Authors | Deligeorgakis, D., Trachana M., Pratsidou-Gertsi P., Dimopoulou D., Haidich A-B., & Garyfallos A. |
Journal | Rheumatol Int |
Volume | 40 |
Issue | 6 |
Pagination | 941-949 |
Date Published | 2020 Jun |
ISSN | 1437-160X |
Abstract | To describe the profile of Enthesitis Related Arthritis' (ERA) patients, in the era of biologic DMARDs (bDMARDs). This retrospective cohort study included patients with ERA monitored on a 3-month schedule for at least 1 year. Their metric assessment included the disease status and damage by applying the contemporary tools clinical-Juvenile Arthritis Disease Activity Score (c-JADAS), Juvenile Spondyloarthritis Disease Activity Index (JSpADA), clinical remission (CR) on/off medication and Juvenile Arthritis Damage Index (JADI). 43 patients (males 26) were enrolled, with a mean disease onset of 10.75 years. Median lag time from diagnosis to bDMARDs was 8.5 months. Patients with sacroiliitis received earlier bDMARDs (hazard ratio, HR 3.26). 36/43 patients achieved CR on medication (median time 11 months), which was correlated with compliance (HR: 3.62). The percentage of CR in patients with or without sacroiliitis was 35% and 63% respectively (p = 0.02). Twenty patients (47%) experienced a flare following CR (75%). The median flare-free survival following CR on/off medication was 42 and 34 months, respectively. At the last evaluation, both median baseline cJADAS and JSpADA dropped to 0, 13/43 patients had a persistent disease activity, while 17/43 and 13/43 patients were in CR on/off medication, respectively. The median patient percentage of CR was 54% and no patient had a JADI > 0. Increased lag time to bDMARDs was associated with increased CR (Odds ratio: 1.48). Early administration of bDMARDs and compliance improved long-term outcome of ERA. Sacroiliitis was a negative prognostic factor with an increased need for bDMARDs and diminished rates of CR. |
DOI | 10.1007/s00296-020-04581-w |
Alternate Journal | Rheumatol Int |
PubMed ID | 32322980 |